Literature DB >> 21743833

Frontiers in Alzheimer's disease therapeutics.

Jeremy G Stone1, Gemma Casadesus, Kasia Gustaw-Rothenberg, Sandra L Siedlak, Xinglong Wang, Xiongwei Zhu, George Perry, Rudy J Castellani, Mark A Smith.   

Abstract

Alzheimer disease (AD) is a progressive neurodegenerative disease which begins with insidious deterioration of higher cognition and progresses to severe dementia. Clinical symptoms typically involve impairment of memory and at least one other cognitive domain. Because of the exponential increase in the incidence of AD with age, the aging population across the world has seen a congruous increase AD, emphasizing the importance of disease altering therapy. Current therapeutics on the market, including cholinesterase inhibitors and N-methyl-D-aspartate receptor antagonists, provide symptomatic relief but do not alter progression of the disease. Therefore, progress in the areas of prevention and disease modification may be of critical interest. In this review, we summarize novel AD therapeutics that are currently being explored, and also mechanisms of action of specific drugs within the context of current knowledge of AD pathologic pathways.

Entities:  

Keywords:  Alzheimer's disease; NMDA antagonists; amyloid; antioxidants; cholinesterase inhibitors; luteinizing hormone; mitochondrial therapy; neurodegenerative drugs; tau

Year:  2011        PMID: 21743833      PMCID: PMC3129861          DOI: 10.1177/2040622310382817

Source DB:  PubMed          Journal:  Ther Adv Chronic Dis        ISSN: 2040-6223            Impact factor:   5.091


  158 in total

1.  Spatial learning deficit in transgenic mice that conditionally over-express GSK-3beta in the brain but do not form tau filaments.

Authors:  Félix Hernández; José Borrell; Carmen Guaza; Jesús Avila; José J Lucas
Journal:  J Neurochem       Date:  2002-12       Impact factor: 5.372

2.  Active glycation in neurofibrillary pathology of Alzheimer disease: N(epsilon)-(carboxymethyl) lysine and hexitol-lysine.

Authors:  R J Castellani; P L Harris; L M Sayre; J Fujii; N Taniguchi; M P Vitek; H Founds; C S Atwood; G Perry; M A Smith
Journal:  Free Radic Biol Med       Date:  2001-07-15       Impact factor: 7.376

3.  Inhibition of glycogen synthase kinase-3 by lithium correlates with reduced tauopathy and degeneration in vivo.

Authors:  Wendy Noble; Emmanuel Planel; Cindy Zehr; Vicki Olm; Jordana Meyerson; Farhana Suleman; Kate Gaynor; Lili Wang; John LaFrancois; Boris Feinstein; Mark Burns; Pavan Krishnamurthy; Yi Wen; Ratan Bhat; Jada Lewis; Dennis Dickson; Karen Duff
Journal:  Proc Natl Acad Sci U S A       Date:  2005-05-02       Impact factor: 11.205

Review 4.  Neuroinflammation and anti-inflammatory therapy for Alzheimer's disease.

Authors:  Amy H Moore; M K O'Banion
Journal:  Adv Drug Deliv Rev       Date:  2002-12-07       Impact factor: 15.470

5.  Anthraquinones inhibit tau aggregation and dissolve Alzheimer's paired helical filaments in vitro and in cells.

Authors:  Marcus Pickhardt; Zuzana Gazova; Martin von Bergen; Inna Khlistunova; Yipeng Wang; Antje Hascher; Eva-Maria Mandelkow; Jacek Biernat; Eckhard Mandelkow
Journal:  J Biol Chem       Date:  2004-11-02       Impact factor: 5.157

6.  O-GlcNAcylation regulates phosphorylation of tau: a mechanism involved in Alzheimer's disease.

Authors:  Fei Liu; Khalid Iqbal; Inge Grundke-Iqbal; Gerald W Hart; Cheng-Xin Gong
Journal:  Proc Natl Acad Sci U S A       Date:  2004-07-12       Impact factor: 11.205

7.  Effects of coenzyme Q(10) administration on its tissue concentrations, mitochondrial oxidant generation, and oxidative stress in the rat.

Authors:  Linda K Kwong; Sergey Kamzalov; Igor Rebrin; Anne-Cécile V Bayne; Chandan K Jana; Paul Morris; Michael J Forster; Rajindar S Sohal
Journal:  Free Radic Biol Med       Date:  2002-09-01       Impact factor: 7.376

Review 8.  Oxidative stress and redox-active iron in Alzheimer's disease.

Authors:  Kazuhiro Honda; Gemma Casadesus; Robert B Petersen; George Perry; Mark A Smith
Journal:  Ann N Y Acad Sci       Date:  2004-03       Impact factor: 5.691

9.  Roles of the mammalian mitochondrial fission and fusion mediators Fis1, Drp1, and Opa1 in apoptosis.

Authors:  Yang-ja Lee; Seon-Yong Jeong; Mariusz Karbowski; Carolyn L Smith; Richard J Youle
Journal:  Mol Biol Cell       Date:  2004-09-08       Impact factor: 4.138

10.  Chronic treatment with the gamma-secretase inhibitor LY-411,575 inhibits beta-amyloid peptide production and alters lymphopoiesis and intestinal cell differentiation.

Authors:  Gwendolyn T Wong; Denise Manfra; Frederique M Poulet; Qi Zhang; Hubert Josien; Thomas Bara; Laura Engstrom; Maria Pinzon-Ortiz; Jay S Fine; Hu-Jung J Lee; Lili Zhang; Guy A Higgins; Eric M Parker
Journal:  J Biol Chem       Date:  2004-01-06       Impact factor: 5.157

View more
  11 in total

Review 1.  Microtubule affinity-regulating kinases are potential druggable targets for Alzheimer's disease.

Authors:  Narendran Annadurai; Khushboo Agrawal; Petr Džubák; Marián Hajdúch; Viswanath Das
Journal:  Cell Mol Life Sci       Date:  2017-06-20       Impact factor: 9.261

Review 2.  Towards the prevention of potential aluminum toxic effects and an effective treatment for Alzheimer's disease.

Authors:  Maire E Percy; Theo P A Kruck; Aileen I Pogue; Walter J Lukiw
Journal:  J Inorg Biochem       Date:  2011-08-19       Impact factor: 4.155

3.  β amyloid peptide plaques fail to alter evoked neuronal calcium signals in APP/PS1 Alzheimer's disease mice.

Authors:  Clark A Briggs; Corinne Schneider; Jill C Richardson; Grace E Stutzmann
Journal:  Neurobiol Aging       Date:  2013-01-18       Impact factor: 4.673

4.  Molecular Assembly and Biosynthesis of Acetylcholinesterase in Brain and Muscle: the Roles of t-peptide, FHB Domain, and N-linked Glycosylation.

Authors:  Vicky P Chen; Wilson K W Luk; Wallace K B Chan; K Wing Leung; Ava J Y Guo; Gallant K L Chan; Sherry L Xu; Roy C Y Choi; Karl W K Tsim
Journal:  Front Mol Neurosci       Date:  2011-10-25       Impact factor: 5.639

5.  In vitro Anti-cholinesterase and Anti-oxidant Activity of Three Standardised Polyherbal Products Used for Memory Enhancing in Ethnomedicine of South-East Nigeria.

Authors:  Lucky Legbosi Nwidu; Ekramy Elmorsy; Wayne Grant Carter
Journal:  Malays J Med Sci       Date:  2018-04-27

6.  Protective effects of Akkermansia muciniphila on cognitive deficits and amyloid pathology in a mouse model of Alzheimer's disease.

Authors:  Zihao Ou; Lulu Deng; Zhi Lu; Feifan Wu; Wanting Liu; Dongquan Huang; Yongzheng Peng
Journal:  Nutr Diabetes       Date:  2020-04-22       Impact factor: 5.097

7.  Posiphen as a candidate drug to lower CSF amyloid precursor protein, amyloid-β peptide and τ levels: target engagement, tolerability and pharmacokinetics in humans.

Authors:  Maria L Maccecchini; Mee Young Chang; Catherine Pan; Varghese John; Henrik Zetterberg; Nigel H Greig
Journal:  J Neurol Neurosurg Psychiatry       Date:  2012-07-11       Impact factor: 10.154

8.  Pharmacological characterization of memoquin, a multi-target compound for the treatment of Alzheimer's disease.

Authors:  Valeria Capurro; Perrine Busquet; Joao Pedro Lopes; Rosalia Bertorelli; Glauco Tarozzo; Maria Laura Bolognesi; Daniele Piomelli; Angelo Reggiani; Andrea Cavalli
Journal:  PLoS One       Date:  2013-02-18       Impact factor: 3.240

9.  Degenerative alterations in noradrenergic neurons of the locus coeruleus in Alzheimer's disease.

Authors:  Lihua Liu; Saiping Luo; Leping Zeng; Weihong Wang; Liming Yuan; Xiaohong Jian
Journal:  Neural Regen Res       Date:  2013-08-25       Impact factor: 5.135

10.  Cotinine halts the advance of Alzheimer's disease-like pathology and associated depressive-like behavior in Tg6799 mice.

Authors:  Sagar Patel; J Alex Grizzell; Rosalee Holmes; Ross Zeitlin; Rosalynn Solomon; Thomas L Sutton; Adeeb Rohani; Laura C Charry; Alexandre Iarkov; Takashi Mori; Valentina Echeverria Moran
Journal:  Front Aging Neurosci       Date:  2014-07-23       Impact factor: 5.750

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.